Alz Res Therapy:简易认知量表测试,或可辅助筛查阿尔兹海默症病理筛查

2021-11-08 Freeman MedSci原创

BHA措施与Aβ和区域tau的体内成像标志物明显相关,可用于识别临床实践中疑似AD病理的患者

一些研究已经调查了认知措施和AD PET病理标志物之间的关系。具体来说,过去的研究发现tau-PET和认知之间有中度到强度的关联,表明tau示踪剂结合的地形与典型和非典型AD相关领域的认知表现相吻合。此外,tau-PET与认知正常的老年人的认知表现和衰退有关,也与混合临床样本的功能损害的严重程度有关。

同样,Aβ-PET负担和认知之间的关系在临床混合样本和认知无障碍样本中都有报道,包括认知正常的Aβ阳性(Aβ+)老年人的下降率更高。

然而,与tau相比,更大的Aβ负担对认知表现的影响往往更弱,这可能是由于tau病理与受影响脑区的神经元损失关系更密切。同时,PET研究在很大程度上仍然是成本高昂,无法广泛使用,仍然需要简短和高效的工具来检测AD病理。考虑到体内标志物与认知的关联,简短、可靠和敏感的认知措施有可能作为一线成本效益的临床标志物满足这一需求。

与Aβ和tau标志物密切相关的及时和具有成本效益的临床标志物可能有助于大大减少临床上对PET扫描的需求,并实现多模式的病例识别,作为漫长的临床和诊断评估的一个可扩展的替代方案。这些非侵入性的一线措施不会取代全面的临床和神经心理学评估以及标准的成像和实验室测试,而是通过为提供者提供一种手段来确定谁需要转诊进行综合评估以进行诊断确认,从而提高这些诊断研究的临床效率。此外,对认知功能的强大的多领域测量将加强PET结果对临床影响和护理路径的实施,特别是考虑到过去对认知无障碍的人的PET阳性结果的证据。


藉此,UCSF的Elena Tsoy等人探讨了加州大学旧金山分校(UCSF)脑健康评估(BHA)的认知表现之间的关联,这是一个基于平板电脑的简短量表,开发并验证了用于检测老年人的神经认知障碍。


他们在轻度认知障碍(MCI)或痴呆症患者(N = 140;43 Aβ-,97 Aβ+)中使用逻辑回归模型研究了基于脑健康评估(BHA)片剂的认知测量与二分法Aβ-PET状态的关系。我们还在60名Aβ+的MCI或痴呆患者的子样本中使用体素明智回归分析,调查了BHA测试和tau-PET信号的区域模式之间的关系。

他们发现:Favorites(联想记忆)、Match(执行功能和速度)和日常认知量表得分与Aβ阳性显著相关(曲线下面积[AUC] = 0.75 [95% CI 0.66-0.85])。

在MCI和痴呆症患者的子样本中,中颞区的Favorites、额顶区的Match和枕顶区的Line Orientation(视觉空间技能)与Tau-PET信号有明显的关联。

这个研究的重要意义在于发现了:BHA措施与Aβ和区域tau的体内成像标志物明显相关,可用于识别临床实践中疑似AD病理的患者



原文出处:
Tsoy E, Strom A, Iaccarino L, et al. Detecting Alzheimer’s disease biomarkers with a brief tablet-based cognitive battery: sensitivity to Aβ and tau PET. Alz Res Therapy. 2021;13(1):36. doi:10.1186/s13195-021-00776-w

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1739082, encodeId=a1d31e3908293, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 21 18:40:48 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402838, encodeId=61391402838b1, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Nov 09 21:40:48 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068332, encodeId=f9cc1068332d2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068331, encodeId=f6f310683312c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:12 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068291, encodeId=92ae10682919a, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Mon Nov 08 22:23:49 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1739082, encodeId=a1d31e3908293, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 21 18:40:48 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402838, encodeId=61391402838b1, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Nov 09 21:40:48 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068332, encodeId=f9cc1068332d2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068331, encodeId=f6f310683312c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:12 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068291, encodeId=92ae10682919a, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Mon Nov 08 22:23:49 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1739082, encodeId=a1d31e3908293, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 21 18:40:48 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402838, encodeId=61391402838b1, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Nov 09 21:40:48 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068332, encodeId=f9cc1068332d2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068331, encodeId=f6f310683312c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:12 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068291, encodeId=92ae10682919a, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Mon Nov 08 22:23:49 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-08 ms1000000493815277

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1739082, encodeId=a1d31e3908293, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 21 18:40:48 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402838, encodeId=61391402838b1, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Nov 09 21:40:48 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068332, encodeId=f9cc1068332d2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068331, encodeId=f6f310683312c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:12 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068291, encodeId=92ae10682919a, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Mon Nov 08 22:23:49 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-08 ms1000000493815277

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1739082, encodeId=a1d31e3908293, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Feb 21 18:40:48 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402838, encodeId=61391402838b1, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Nov 09 21:40:48 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068332, encodeId=f9cc1068332d2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068331, encodeId=f6f310683312c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211108/e2bd4fbd41934073b5b4642cc3ed6be5/e025ada6c52248628122bf623088bde7.jpg, createdBy=6ee35699707, createdName=ms1000000493815277, createdTime=Mon Nov 08 23:51:12 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068291, encodeId=92ae10682919a, content=坚持学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Mon Nov 08 22:23:49 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-08 SR~young海东

    坚持学习

    0

相关资讯

Alz Res Therapy:遗传变异或揭示AD发病的潜在机制

遗传变异可能在AD发病机制中发挥功能作用并提出潜在机制。

Alz Res Therapy:认知正常老年人,高强度体育锻炼,会让大脑更灵光吗?

运动强度对心肺功能的影响是剂量依赖性的,高强度组的体能比中等强度组和对照组有更大的提高。然而,运动对认知能力没有直接影响。

Alzheimer Dementia:血浆置换加白蛋白明显改善老年痴呆患者记忆力和生活质量!

PE治疗的AD患者在记忆力、语言能力、处理速度和QoL-AD方面都有改善。

Alz Res Therapy:基因风险评分,和血液磷酸化tau蛋白息息相关

包括APOE在内的AD多基因风险与血浆p-tau181有关,与诊断和Aβ病理状态无关

Alz Res Therapy:白质高信号和痴呆影像指标,关系千丝万缕

该结果强调了WMH的模式特异性分布模式,这些模式在后部白质中汇聚。

Alz Res Therapy:阿尔兹海默和路易体痴呆,APOE ε4对认知表现的影响不同

与非携带者相比,APOE ε4携带者的特定初始认知症状的几率在ADP和LRP之间存在差异。

拓展阅读

Alzheimer Dementia:从患者和护理的角度看阿尔茨海默病生物标志物检测和结果

有痴呆生活经验者的观点为生物标志物检测的价值提供了新的视角,应作为证据指导下的检测前咨询和结果考虑因素的一部分。

Annals of Neurology:AD相关生物标志物对皮质基底综合征和进行性核上性麻痹的影响

AD生物标志物阳性可能会改变CBS/PSP的临床表现,并有证据表明与AD病理/共病理相关的独特的大脑结构和功能变化。

IJNS:基于生命历程模型的多领域干预可降低老年人痴呆的风险

基于生命历程模型的多领域干预是可行的,有可能降低中国高危老年人患痴呆症的风险,改善他们的认知功能。

ART:视网膜血管的变化有望为观测阿尔茨海默病进程提供一个窗口

视网膜血管测量并不能代表非痴呆个体的脑血管损伤,而鼻侧象限的VD与海马萎缩相关,与淀粉样蛋白状态无关。

Neurology:利用基于弥散的神经炎症成像技术研究阿尔茨海默病的白质神经炎症

WM神经炎症在AD临床症状出现之前就已发生改变,并且与淀粉样变性相互作用。

Nature子刊:与记忆力训练相比,瑜伽对老年痴呆高危妇女的认知和免疫学影响

KY 对 SCD 有临床和生物学上的益处,将认知的变化与瑜伽的抗炎作用联系起来。

2022 欧洲共识:MCI和轻度痴呆初级阶段的诊断和治疗

意大利阿尔兹海默病专家组 · 2022-10-09

适合痴呆症患者的急救护理:老年急救护理应用研究网络范围审查和共识会议的结果

急性期后和长期护理学会(AMDA,The Society for Post-Acute and Long-Term Care Medicine) · 2022-08-01

痴呆及阿尔茨海默病进展要点简析

四川大学华西医院 · 2022-07-26